BACKGROUND: Despite convenience, accessibility, and strong correlation to severity of Alzheimer disease (AD) pathology, medial temporal lobe atrophy (MTA) has not been used as a criterion in the diagnosis of prodromal and probable AD. METHODS: Using a newly validated visual rating system, mean MTA scores of three bilateral medial temporal lobe structures were compared for subjects with no cognitive impairment (NCI) (n = 117), nonamnestic mild cognitive impairment (MCI) (n = 46), amnestic MCI (n = 45), and probable AD (n = 53). Correlations between MTA scores and neuropsychological test scores at baseline, and predictors of change in diagnosis at 1-year follow-up were evaluated. RESULTS: With NCI as the reference group, a mean MTA cut score of 1.33 yielded an optimal sensitivity/specificity of 85%/82% for probable AD subjects and 80%/82% for amnestic MCI subjects. MTA and Clinical Dementia Rating Sum of Boxes scores at baseline were independent and additive predictors of diagnosis at baseline, and of transition from NCI to MCI or from MCI to dementia at 1-year follow-up. CONCLUSION: Medial temporal lobe atrophy (MTA) scores 1) distinguish probable Alzheimer disease (AD) and amnestic mild cognitive impairment (MCI) subjects from nonamnestic MCI and no cognitive impairment (NCI) subjects, 2) help predict diagnosis at baseline, and 3) predict transition from NCI to MCI and from MCI to probable AD. MTA scores should be used as a criterion in the clinical diagnosis of AD.
BACKGROUND: Despite convenience, accessibility, and strong correlation to severity of Alzheimer disease (AD) pathology, medial temporal lobe atrophy (MTA) has not been used as a criterion in the diagnosis of prodromal and probable AD. METHODS: Using a newly validated visual rating system, mean MTA scores of three bilateral medial temporal lobe structures were compared for subjects with no cognitive impairment (NCI) (n = 117), nonamnestic mild cognitive impairment (MCI) (n = 46), amnestic MCI (n = 45), and probable AD (n = 53). Correlations between MTA scores and neuropsychological test scores at baseline, and predictors of change in diagnosis at 1-year follow-up were evaluated. RESULTS: With NCI as the reference group, a mean MTA cut score of 1.33 yielded an optimal sensitivity/specificity of 85%/82% for probable AD subjects and 80%/82% for amnestic MCI subjects. MTA and Clinical Dementia Rating Sum of Boxes scores at baseline were independent and additive predictors of diagnosis at baseline, and of transition from NCI to MCI or from MCI to dementia at 1-year follow-up. CONCLUSION: Medial temporal lobe atrophy (MTA) scores 1) distinguish probable Alzheimer disease (AD) and amnestic mild cognitive impairment (MCI) subjects from nonamnestic MCI and no cognitive impairment (NCI) subjects, 2) help predict diagnosis at baseline, and 3) predict transition from NCI to MCI and from MCI to probable AD. MTA scores should be used as a criterion in the clinical diagnosis of AD.
Authors: Adam S Fleisher; Rema Raman; Eric R Siemers; Lida Becerra; Christopher M Clark; Robert A Dean; Martin R Farlow; James E Galvin; Elaine R Peskind; Joseph F Quinn; Abdullah Sherzai; B Brooke Sowell; Paul S Aisen; Leon J Thal Journal: Arch Neurol Date: 2008-08
Authors: D A Loewenstein; W W Barker; D G Harwood; C Luis; A Acevedo; I Rodriguez; R Duara Journal: Int J Geriatr Psychiatry Date: 2000-05 Impact factor: 3.485
Authors: K Pérès; V Chrysostome; C Fabrigoule; J M Orgogozo; J F Dartigues; P Barberger-Gateau Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: Charles DeCarli; Giovanni B Frisoni; Christopher M Clark; Danielle Harvey; Michael Grundman; Ronald C Petersen; Leon J Thal; Shelia Jin; Clifford R Jack; Philip Scheltens Journal: Arch Neurol Date: 2007-01
Authors: M Bobinski; M J de Leon; J Wegiel; S Desanti; A Convit; L A Saint Louis; H Rusinek; H M Wisniewski Journal: Neuroscience Date: 2000 Impact factor: 3.590
Authors: F Barkhof; T M Polvikoski; E C W van Straaten; R N Kalaria; R Sulkava; H J Aronen; L Niinistö; S Rastas; M Oinas; P Scheltens; T Erkinjuntti Journal: Neurology Date: 2007-10-09 Impact factor: 9.910
Authors: Marcus Likeman; Valerie M Anderson; John M Stevens; Adam D Waldman; Alison K Godbolt; Chris Frost; Martin N Rossor; Nick C Fox Journal: Arch Neurol Date: 2005-09
Authors: Shanna L Burke; Tianyan Hu; Mitra Naseh; Nicole M Fava; Janice O'Driscoll; Daniel Alvarez; Linda B Cottler; Ranjan Duara Journal: Aging Clin Exp Res Date: 2018-12-10 Impact factor: 3.636
Authors: Ranjan Duara; David A Loewenstein; Maria T Greig-Custo; Ashok Raj; Warren Barker; Elizabeth Potter; Elizabeth Schofield; Brent Small; John Schinka; Yougui Wu; Huntington Potter Journal: Int J Geriatr Psychiatry Date: 2010-03 Impact factor: 3.485
Authors: Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson Journal: Nat Rev Neurol Date: 2010-02 Impact factor: 42.937
Authors: Rani A Sarkis; Louis Beers; Emile Farah; Mohammad Al-Akaidi; Yuxiang Zhang; Joseph J Locascio; Michael J Properzi; Aaron P Schultz; Jasmeer P Chhatwal; Keith A Johnson; Reisa A Sperling; Page B Pennell; Gad A Marshall Journal: Clin Neurophysiol Date: 2020-09-19 Impact factor: 3.708